INTERLEUKIN-1β AND TUMOR NECROSIS FACTOR-α GENE POLYMORPHISMS IN SYSTEMIC SCLEROSIS
Hakami M.A1, Alotaibi B.S1, Alkhalil S.S1, Das S2, Nasreen N3, Jeraiby M.A4, Jawed A5, Lohani M5, Dar S.A5*
*Corresponding Author: *Corresponding Author: Sajad Ahmad Dar, Department of Nursing, College of Nursing and Health Sciences, Jazan University, Jazan 45142, Saudi Arabia; Email: sdar@jazanu.edu.sa
page: 59
|
|
REFERENCES
1.
Steen VD, Medsger TA. Epidemiology and natural
history of systemic sclerosis. Rheum Dis Clin North
Am. 1990; 16(1):1-10.
2.
Medsger TA Jr. Epidemiology of systemic sclerosis.
Clin Dermatol. 1994; 12(2):207- 216.
3.
Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Pre-
dicting mortality in systemic sclerosis: Analysis of a
cohort of 309 French Canadian patients with empha-
sis on features at diagnosis as predictive factors for
survival. Medicine (Baltimore). 2002; 81(2):154-67.
4.
Shand L, Lunt M, Nihtyanova S, et al. Relationship
between change in skin score and disease outcome
in diffuse cutaneous systemic sclerosis: Application of a latent linear trajectory model. Arthritis Rheum.
2007; 56(7):2422-2431.
5.
Burchfield C, Vorrasi J. Maxillofacial Implications
of Scleroderma and Systemic Sclerosis: A Case Re-
port and Literature Review. J Oral Maxillofac Surg.
2019;77(6):1203-1208.
6.
Sozeri B, Gulez N, Aksu G, et al. Pesticide-induced
scleroderma and early intensive immunosuppres-
sive treatment. Arch Environ Occup Health. 2012;
67(1):43-47.
7.
Pollard KM, Pearson DL, Hultman P, et al. Lupus-
prone mice as models to study xenobiotic-induced ac-
celeration of systemic autoimmunity. Environ Health
Perspect. 1999; 107(Suppl 5):729735.
8.
Wynn TA. Fibrotic disease and the T (H) 1 / T (H) 2
paradigm. Nat Rev Immunol. 2004; 4(8):583594.
9.
Granel B, Chevillard C, Allanore Y, et al. Evaluation
of interleukin 13 polymorphisms in systemic sclero-
sis. Immunogenetics. 2006;58(8):693699.
10. Matsushita T, Hasegawa M, Hamaguchi Y, et al. Lon-
gitudinal analysis of serum cytokine concentrations
in systemic sclerosis: association of interleukin 12
elevation with spontaneous regression of skin scle-
rosis. J Rheumatol. 2006; 33(2):275284.
11. Mavalia C, Scaletti C, Romagnani P, et al. Type
2 helper T-cell predominance and high CD30 ex-
pression in systemic sclerosis. Am J Pathol. 1997;
151(6):17511758.
12. Hoffmann SC, Stanley EM, Darrin Cox E, et al. As-
sociation of cytokine polymorphic inheritance and in
vitro cytokine production in anti-CD3/CD28-stimu-
lated peripheral blood lymphocytes. Transplantation.
2001;72(8):14441450.
13. Suarez A, Castro P, Alonso R, et al. Inter-individ-
ual variations in constitutive interleukin-10 mes-
senger RNA and protein levels and their associa-
tion with genetic polymorphisms. Transplantation.
2003;75(5):711717.
14. Xu D, Mu R, Wei X. The Roles of IL-1 Family Cy-
tokines in the Pathogenesis of Systemic Sclerosis.
Front Immunol. 2019;10:2025.
15. Hutyrova B, Lukac J, Bosak V, et al. Interleukin 1_
single nucleotide polymorphism associated with sys-
temic sclerosis. J Rheumatol. 2004;31(1):8184.
16. Beretta L, Bertolotti F, Cappiello F, et al. Interleukin-1
gene complex polymorphisms in systemic sclerosis
patients with severe restrictive lung physiology. Hum
Immunol. 2007a; 68(7):603 609.
17. Mattuzzi S, Barbi S, Carletto A, et al. Association
of polymorphisms in the IL1B and IL2 genes with
susceptibility and severity of systemic sclerosis. J
Rheumatol. 2007; 34(5):9971004.
18. Crilly A, Hamilton J, Clark CJ, et al. Analysis of
the 5 flanking region of the interleukin 10 gene in
patients with systemic sclerosis. Rheumatology (Ox-
ford). 2003;42(11):12951298.
19. Beretta L, Cappiello F, Barili M, et al. Proximal in-
terleukin-10 gene polymorphisms in Italian patients
with systemic sclerosis. Tissue Antigens. 2007b;
69(4):305312.
20. Subcommittee for Scleroderma Criteria of the Ameri-
can Rheumatism Association Diagnostic and Thera-
peutic Criteria Committee. Preliminary criteria for the
classification of systemic sclerosis (scleroderma) Ar-
thritis Rheum. 1980;23:58190.
21. Katsumoto TR, Whitfield ML, Connolly MK. The
pathogenesis of systemic sclerosis. Ann Rev Pathol.
2011; 6:509-537.
22. Hurme M, Lahdenpohja N, Santtila S. Gene poly-
morphisms of interleukins 1 and 10 in infectious and
autoimmune diseases. Ann Med. 1998; 30(5):469-
473.
23. Hwang IR, Kodama T, Kikuchi S, et al. Effect of
interleukin 1 polymorphisms on gastric mucosal
interleukin 1beta production in Helicobacter pylori
infection. Gastroenterology. 2002;123(6):1793- 1803.
24. Iacoviello L, Di Castelnuovo A, Gattone M, et al.
Polymorphisms of the interleukin- 1beta gene affect
the risk of myocardial infarction and ischemic stroke
at young age and the response of mononuclear cells to
stimulation in vitro. Arterioscler Thromb Vasc Biol.
2005;25(1):222-227.
25. Wen AQ, Gu W, Wang J, et al. Clinical relevance
of IL- 1β promoter polymorphisms (-1470,-511,
and-31) in patients with major trauma. Shock. 2010;
33(6):576582.
26. Yin WT, Pan YP, Lin L. Association between IL-
1α rs17561 and IL-1β rs1143634 polymorphisms
and periodontitis: a meta-analysis. Genet Mol Res.
2016;15(1).
27. Lavu V, Venkatesan V, Venugopal P, et al. Clini-
cal Relevance of Cytokines Gene Polymorphisms
and Protein Levels in Gingival Cervical Fluid from
Chronic Periodontitis Patients. Iran J Immunol.
2017;14(1):51-58.
28. Jagadish R, Mehta DS, Jagadish P. Oral and periodon-
tal manifestations associated with systemic sclerosis:
a case series and review. J Indian Soc Periodontol.
2012;16(2):271274.
29. Grewal IS. Overview of TNF superfamily: a chest
full of potential therapeutic targets. Adv Exp Med
Biol. 2009;647:1-7.
30. Kantor TV, Frieberg D, Medsger TA Jr, et al. Cytokine
production and serum levels in systemic sclerosis.
Clin Immunol Immunopathol. 1992;65(3):278-285.
31. Young V, Ho M, Vosper H, et al. Elevated expression
of the genes encoding TNF-alpha and thromboxane
synthase in leukocytes from patients with systemic scle-
rosis. Rheumatology (Oxford). 2002; 41(8):869-875.
32. Bolster MB, Ludwicka A, Sutherland SE, et al. Cy-
tokine concentrations in bronchoalveolar lavage fluid
of patients with systemic sclerosis. Arthritis Rheum.
1997; 40(4):743-751.
33. Mathai SK, Gulati M, Peng X, et al. Circulating
monocytes from systemic sclerosis patients with in-
terstitial lung disease show an enhanced profibrotic
phenotype. Lab Invest. 2010; 90(6):812-823.
34. Azab E, Elfasakhany FM. Effect of tumor necrosis
factor alpha (TNF-α) -308 and -1031 gene polymor-
phisms on periodontitis among Saudi subjects. Saudi
Dent J. 2022;34(3):226-231.
35. Huizinga TW, Westendorp RG, Bollen EL, et al. TNF-
alpha promoter polymorphisms, production, and sus-
ceptibility to multiple sclerosis in different groups of
patients. J Neuroimmunol. 1997; 72(2):149153.
36. Tolusso B, Fabris M, Caporali R, et al. -238 and +489
TNF-alpha along with TNF-RII gene polymorphisms
associate with the diffuse phenotype in patients with
systemic sclerosis. Immunol Lett. 2005;96(1):103108.
37. Perrey C, Pravica V, Sinnott PJ, et al. Genotyping
for polymorphisms in interferon-γ, interleukin-10,
transforming growth factor-β1 and tumor necrosis
factor- α genes: a technical report. Transpl Immunol.
1998; 6(3):193197.
38. Saremi L, Shafizadeh M, Ghaffari ME, et al. Evalu-
ation of interleukin 10, interleukin 1-beta, and tumor
necrosis factor-alpha gene polymorphisms in patients
with periodontitis and healthy controls. Egypt J Med
Hum Genet. 2022;23:157.
39. Zhou Y, Gsicombe R, Huang D, et al. Novel genetic
association of Wegeners granulomatosis with the in-
terleukin-10 gene. J Rheumatol. 2002; 29(2):317320.
40. Crilly A, Hamilton J, Clark CJ, et al. Analysis of
transforming growth factor β1 gene polymorphisms
in patients with systemic sclerosis. Ann Rheum Dis.
2002; 61(8):678681.
41. Sugiura Y, Banno S, Matsumoto Y, et al. Transform-
ing growth factor beta1 gene polymorphism in pa-
tients with systemic sclerosis. J Rheumatol. 2003;
30(7):15201523.
42. Peoples C, Medsger TA Jr, Lucas M, et al. Gender
differences in systemic sclerosis: relationship to clini-
cal features, serologic status and outcomes. J Sclero-
derma Relat Disord. 2016;1(2):177-240.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
